Monday, August 24, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· May 21, 2026

Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types

View original at finance.yahoo.com
Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types – Findings in neuroendocrine tumors, kidney cancer, advanced colorectal cancer and other tumors to be presented – ALAMEDA, Calif., May 21, 2026--(BUSINESS WIRE)--Exelixis, Inc…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The collective ASCO 2026 data sets demonstrate Exelixis's dedication to improving standards of care for patients with cancer

    60% confidence

  • Findings from the phase 3 STELLAR-303 pivotal trial evaluating zanzalintinib in metastatic colorectal cancer will be presented at ASCO 2026

    60% confidence

  • New analyses from the phase 3 CABINET pivotal trial further reinforce the foundational role of CABOMETYX in patient care

    60% confidence

  • In 2016, Exelixis granted Ipsen Pharma SAS exclusive rights for the commercialization and further clinical development of cabozantinib outside of the U.S. and Japan

    60% confidence

  • In 2017, Exelixis granted Takeda Pharmaceutical Company Limited exclusive rights for cabozantinib commercialization and development for all future indications in Japan

    60% confidence

  • CABOMETYX tablets have received regulatory approvals in over 65 countries outside the U.S. and Japan, including the EU

    60% confidence

  • The ASCO 2026 presentations highlight continued progress of Exelixis's strategy to build upon the well-established therapeutic profile of CABOMETYX and accelerate the development of zanzalintinib as the next oncology franchise molecule

    60% confidence

  • Exelixis holds the exclusive rights to develop and commercialize cabozantinib in the U.S.

    60% confidence

Cited in these Via News reports